These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 9118815)

  • 1. Choosing the right lipid-regulating agent. A guide to selection.
    Farmer JA; Gotto AM
    Drugs; 1996 Nov; 52(5):649-61. PubMed ID: 9118815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR; Bacon S
    Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Currently available hypolipidaemic drugs and future therapeutic developments.
    Farmer JA; Gotto AM
    Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):825-47. PubMed ID: 8593127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    Schiel R; Bambauer R; Müller UA
    Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choice of cholesterol-lowering drugs.
    Med Lett Drugs Ther; 1993 Mar; 35(891):19-22. PubMed ID: 8433674
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of hypercholesterolaemia in postmenopausal women.
    Davidson MH; Maki KC; Karp SK; Ingram KA
    Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current pharmacologic treatment of elevated serum cholesterol.
    Tikkanen MJ; Nikkilä EA
    Circulation; 1987 Sep; 76(3):529-33. PubMed ID: 3476221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of hyperlipidemia and the role of probucol.
    Davignon J
    Am J Cardiol; 1986 Jun; 57(16):22H-28H. PubMed ID: 3460320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
    Farnier M
    Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB; Peters JR
    Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
    Erkelens DW
    Cardiology; 1990; 77 Suppl 4():33-8. PubMed ID: 2073670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering agents in proteinuric diseases.
    Appel GB; Appel AS
    Am J Nephrol; 1990; 10 Suppl 1():110-5. PubMed ID: 2256470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
    McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
    Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
    Brown WV
    Cardiology; 1989; 76 Suppl 1():45-51; discussion 52-4. PubMed ID: 2653623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
    Schectman G; Hiatt J
    Am J Med; 1996 Feb; 100(2):197-204. PubMed ID: 8629655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.